{"entity":{"id":"nectin4","kind":"target","name":"Nectin-4","aka":[],"tldr":"Nectin-4 is an adhesion protein plentiful on bladder cancer cells, used as the docking site for the ADC enfortumab vedotin.","summary":"Nectin-4 is expressed at high levels in urothelial carcinoma and also in breast, lung, and pancreatic cancers. Enfortumab vedotin plus pembrolizumab is first-line standard in advanced urothelial cancer (EV-302). Next-generation Nectin-4 ADCs with topoisomerase-I payloads (MK-3120) and Nectin-4×TROP2 bispecific ADCs (AK146D1, AVZO-103) are in development.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Nectin-4","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Nectin-4"}],"tags":["adc-target"],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"NECTIN4","hgnc":"HGNC:19688","ensembl":"ENSG00000143217","uniprot":"Q96NY8","entrez":"81607","biology":"Nectin-4 is a cell adhesion molecule and also a receptor for measles virus. Skin expression explains the rash seen with enfortumab.","whereFound":["Urothelial carcinoma (>80%)","TNBC","NSCLC","Pancreatic"],"targetClass":"surface-antigen","prevalence":[]},"route":"/targets/nectin4/","neighbours":{"technology":[{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/"}],"company":[{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/"}],"indication":[{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/"}],"opportunity":[{"id":"opp-nectin4-imaging-urothelial","kind":"opportunity","name":"A liver-cleared Nectin-4 tracer for urothelial cancer","route":"/opportunities/opp-nectin4-imaging-urothelial/"}]}}